186 related articles for article (PubMed ID: 37991046)
21. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
[TBL] [Abstract][Full Text] [Related]
22. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
23. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
24. Novel therapy for childhood acute lymphoblastic leukemia.
Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
Temple WC; Mueller S; Hermiston ML; Burkhardt B
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101449. PubMed ID: 36907639
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
[TBL] [Abstract][Full Text] [Related]
28. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
Kebriaei P; Poon ML
Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
[TBL] [Abstract][Full Text] [Related]
29. [CAR-T therapy for pediatric acute lymphoblastic leukemia].
Sakaguchi H
Rinsho Ketsueki; 2023; 64(11):1440-1446. PubMed ID: 38072432
[TBL] [Abstract][Full Text] [Related]
30. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
31. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
32. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy.
Kotecha RS
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):611-617. PubMed ID: 36485124
[TBL] [Abstract][Full Text] [Related]
33. Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia.
McNeer JL; Rau RE; Gupta S; Maude SL; O'Brien MM
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-12. PubMed ID: 32320280
[TBL] [Abstract][Full Text] [Related]
34. Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects.
Li W; Zhang Y; Kankala RK; Zou L; Chen Z
Pharmacology; 2022; 107(7-8):368-375. PubMed ID: 35390793
[TBL] [Abstract][Full Text] [Related]
35. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
36. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Tran TH; Hunger SP
Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
[TBL] [Abstract][Full Text] [Related]
37. Novel Therapies in Acute Lymphoblastic Leukemia.
Phelan KW; Advani AS
Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
[TBL] [Abstract][Full Text] [Related]
38. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
39. Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis.
Rajagopala SV; Yooseph S; Harkins DM; Moncera KJ; Zabokrtsky KB; Torralba MG; Tovchigrechko A; Highlander SK; Pieper R; Sender L; Nelson KE
BMC Genomics; 2016 Aug; 17(1):635. PubMed ID: 27527070
[TBL] [Abstract][Full Text] [Related]
40. Novel and emerging drugs for acute lymphoblastic leukemia.
Lech-Maranda E; Mlynarski W
Curr Cancer Drug Targets; 2012 Jun; 12(5):505-21. PubMed ID: 22483156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]